RESEARCH PAPER

From Monoclonal to Multifunctional: The Evolving Landscape of Engineered Antibodies

Kamali M L[1], Tha Thayuamanavan[1], Preethi Vardhana S[1], Sultan Mohaideen H[1], Dimpal N[1], Hashika SK[1]

[1] Department of Biotechnology, KIT-Kalaignarkarunanidhi Institute of Technology, Coimbatore, India.

ABSTRACT

Antibodies play a crucial role in the adaptive immune system by accurately identifying and neutralizing pathogens, toxins, and irregular cells. Their structural configuration comprising heavy and light chains, antigen-binding fragments (Fab), and crystallizable fragments (Fc) is critical to their specificity and functional flexibility, serving both as immune components and therapeutic agents. Over recent decades, breakthroughs in molecular biology and protein engineering have revolutionized antibody technology, transitioning from conventional hybridoma-derived monoclonal antibodies to recombinant and fully human antibodies. Phage display has pioneered the large-scale discovery of antibodies, while yeast and mammalian display systems have introduced eukaryotic folding and post-translational modifications, facilitating the selection of high-quality therapeutic candidates. Site-directed mutagenesis has emerged as a fundamental technique in antibody engineering, enabling targeted optimization of complementarity-determining regions to improve affinity, specificity, and stability. Concurrently, ribosome and mRNA display technologies have allowed for in vitro screening of extremely large libraries, bypassing host transformation hurdles and speeding up the evolution of high-performance antibody variants. Collectively, these integrated strategies create a robust pipeline for rational antibody design, affinity maturation, and the development of next-generation biologics. This review brings together historical milestones, technological advancements, and state-of-the-art engineering techniques, offering a thorough overview of how antibody engineering continuously influences biomedical research, diagnostics, and the discovery of therapeutic drugs.

Keywords: Monoclonal antibodies, Recombinant antibodies, Phage display, Yeast display, Mammalian display, Ribosome display, mRNA display, Site-directed mutagenesis, Affinity maturation

How to cite this article: Kamali M L, Tha Thayuamanavan, Preethi Vardhana S, Sultan Mohaideen H, Dimpal N, Hashika SK. From Monoclonal to Multifunctional: The Evolving Landscape of Engineered Antibodies. Int J Drug Deliv Technol. 2026;16(37s): 231-253. DOI: 10.25258/ijddt.16.37s.32

Source of support: Nil.

Conflict of interest: None

INTRODUCTION

IMPORTANCE OF ANTIBODIES

Antibodies, known as immunoglobulins (Ig), are specific glycoproteins produced by B lymphocytes as part of the adaptive immune response. They are vital in identifying and neutralizing pathogens such as bacteria, viruses, fungi, and toxins. The most notable characteristic of antibodies is their high specificity for antigens-distinct molecular markers found on the surfaces of foreign entities. This specificity enables antibodies to be precise targeting agents that trigger various immune responses.

One of the main functions of antibodies is neutralization, where the antibody attaches directly to a pathogen or toxin, preventing it from entering host cells or disrupting cellular activities. This mechanism is particularly essential in thwarting viral infections, such as those caused by influenza or SARS-CoV-2, where neutralizing antibodies can obstruct viral entry by targeting surface glycoproteins[1]. Another important role is opsonization, the process by which antibodies coat a pathogen to improve its recognition and uptake by phagocytic cells like macrophages and neutrophils[2]. The Fc region of the antibody interacts with Fc receptors on phagocytes, aiding in the engulfment and destruction of the pathogen covered by antibodies. This not only eliminates the infection but also halts its further spread.

Antibodies also activate the classical complement pathway-part of the innate immune system. When antibodies (notably IgG or IgM) bind to an antigen, they trigger complement proteins, which lead to the assembly of the membrane attack complex (MAC)[3]. This complex forms pores in the pathogen's membrane, resulting in cell lysis. The activation of complement additionally enhances opsonization and stimulates inflammation by attracting immune cells to the site of infection. A distinctive process mediated by antibodies is known as antibody-dependent cellular cytotoxicity (ADCC). In ADCC, antibodies bind to antigens located

on the surfaces of infected or abnormal cells. Natural killer (NK) cells recognize these antibody-covered cells via their Fcγ receptors and discharge cytotoxic granules that trigger apoptosis in the targeted cell. This mechanism plays a vital role in the defense against virus-infected and tumor cells[4].

Furthermore, antibodies are essential in developing immunological memory. During an initial immune response, some B cells differentiate into memory B cells, which remain in the body for an extended period. Upon subsequent exposure to the same pathogen, these memory cells quickly reactivate and generate substantial amounts of high-affinity antibodies, ensuring a more rapid and robust secondary immune response. In addition to their innate functions in immune defense, antibodies serve as the foundation of contemporary medicine. Their accuracy and adaptability have paved the way for creating vaccines, monoclonal antibody treatments, diagnostic tools, and antibody-based drug delivery systems. Therapeutically, engineered antibodies help treat many conditions, such as cancer, autoimmune diseases, and infections.

EMERGENCE OF ANTIBODY ENGINEERING

Antibody engineering has become a groundbreaking field since the late 20th century due to progress in molecular biology, recombinant DNA technology, and immunology. The initial monoclonal antibodies were developed using hybridoma technology in 1975 by Köhler and Milstein; however, their mouse origin restricted their efficacy, leading to immune reactions in human recipients[5]. This limitation led to the creation of engineered antibodies capable of maintaining antigen specificity while minimizing immunogenicity. In the 1980s and 1990s, advancements such as chimerization-where murine constant regions were swapped with human ones-and humanization, which involved fitting murine antigen-binding sites onto human antibody structures, greatly enhanced clinical compatibility. The introduction of phage display technology, developed by George P. Smith, allowed for the generation and in vitro screening of antibody fragments to find those with high affinity and specificity, enabling selection without immunization. Further innovations led to the production of fully human antibodies using transgenic mice and in vitro display methods[6]. The field quickly expanded to encompass bispecific antibodies, antibody-drug conjugates (ADCs), nanobodies, and Fc engineering to improve half-life, effector functions, and tissue access. These enhancements have considerably broadened the therapeutic and diagnostic uses of antibodies, particularly in cancer treatment, infectious diseases, and autoimmune conditions. The rise of antibody engineering has shifted passive immunotherapy from traditional polyclonal serum preparations to precisely designed biologics with clear mechanisms of action and enhanced safety profiles.

BASICS OF ANTIBODY STRUCTURE AND FUNCTION

Ig G STRUCTURE AND OVERVIEW

Immunoglobulin G (IgG) is the antibody isotype most commonly found in human serum, playing a critical role in the secondary immune response. An IgG molecule features a Y-shaped glycoprotein structure made up of four polypeptide chains: two identical heavy (H) chains and two identical light (L) chains, which are connected by disulfide bonds and non-covalent interactions.

Light Chains

Each light chain weighs around 25 kDa and is made up of two domains:

Variable domain (VL): This domain is responsible for binding to antigens and shows significant variability among different antibodies, thus contributing to their specificity for antigens.

Constant domain (CL): This domain is less variable and serves to provide structural stability.

Humans possess two types of light chains namely kappa (κ) and lambda (λ). An individual antibody is composed of either two κ or two λ light chains, but not both.

Heavy Chains

Each heavy chain is approximately 50 kDa and consists of four domains:

One variable domain (VH): This domain pairs with the VL domain of the light chain to form the site that binds to antigens.

Three constant domains (CH1, CH2, CH3): These domains define the antibody's isotype and facilitate interactions with immune cells through Fc receptors[7].

The subclasses of IgG (e.g., IgG1, IgG2, IgG3, or IgG4) are determined by the heavy chains and each subclass has distinct biological characteristics and effector functions, including complement activation and binding to Fc receptors.

Antigen-Binding Sites (Fab Region)

The Fab (Fragment antigen-binding) region comprises one complete light chain (VL + CL) along with the VH and CH1 domains of one heavy chain. There are two identical Fab arms on each IgG molecule, allowing for bivalency to antigens.

Fc Region

The CH2 and CH3 domains of the heavy chains constitute the Fc (Fragment crystallizable) region. This region has several functions, including the binding to Fc receptors located on immune cells like macrophages and NK cells, the activation of the complement system through C1q, and the regulation of the antibody's lifespan.

Hinge Region

Located between the Fab and Fc regions is the hinge region, which is rich in proline and cysteine residues. This region provides flexibility to the antibody arms, enabling them to adopt various angles for effective antigen binding.

Glycosylation

The Fc region of IgG contains a conserved N-linked glycosylation site at Asn297, which is situated in the CH2 domain. Glycosylation affects an antibody's stability, functionality, and its interactions with Fc receptors and the complement system.[8].

ANTIGEN-BINDING SITES (Fab) AND Fc REGION

Fab Region (Fragment Antigen-Binding)

The Fab (Fragment antigen-binding) portion of an antibody specifically attaches to an antigen. Each IgG antibody features two Fab arms, making it bivalent, which means it can simultaneously bind two identical epitopes.

Structure: The Fab consists of a single light chain (comprising a variable (VL) and constant (CL) domain), the N-terminal section of one heavy chain (which includes the variable (VH) and CH1 domains). These domains create a β-sheet "sandwich" configuration, held together by intra-chain disulfide bonds.

Antigen Recognition: The VH and VL domains come together to create the area that attaches to the antigen. Within these domains are three hypervariable loops known as complementarity-determining regions (CDRs), which are designated as CDR1, CDR2, and CDR3. CDR3 exhibits the highest variability and is crucial for determining antigen specificity. The framework regions (FRs) that encase the CDRs contribute to preserving the overall structure[9].

Function: It binds to particular epitopes on antigens via non-covalent interactions like hydrogen bonds, van der Waals forces, and electrostatic forces. This attachment can neutralize pathogens, block receptor interactions, or mark antigens for elimination by the immune system.

Fc Region (Fragment Crystallizable)

The Fc region constitutes the stem of the Y-shaped antibody and is essential for facilitating the immune system's effector functions. It does not directly bind to antigens but interacts with receptors on immune cells and complement proteins.

Structure: It is composed of the CH2 and CH3 domains from the two heavy chains. The CH2 domain features a conserved N-glycosylation site at Asn297, which plays a vital role in the functionality and stability of the Fc region.

Effector Functions

Fcγ Receptor Binding (FcγRs): The Fc region attaches to receptors found on immune cells like macrophages, natural killer (NK) cells, and neutrophils. This binding initiates processes such as antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis.

Complement Activation: Binding with the C1q protein starts the classical complement pathway, resulting in pathogen lysis and inflammation[10].

FcRn-Mediated Recycling: The neonatal Fc receptor (FcRn) attaches to Fc in acidic endosomes, protecting IgG from degradation in lysosomes and prolonging its half-life[11].

Transport Across Cells: FcRn also facilitates the transcytosis of IgG across epithelial barriers (for instance, from mother to fetus via the placenta).

Glycosylation Importance: Glycans at Asn297 influence the structure and flexibility of the Fc region, the binding interactions with FcγRs and C1q, Pro- or anti-inflammatory signaling.

LIMITATIONS OF NATURAL ANTIBODIES

Natural antibodies, which are generated by B cells without prior exposure to antigens or through classical hybridoma techniques, are important for immune defense and diagnostics. Nonetheless, their application as therapeutic agents is constrained by various biological and technical challenges. Firstly, the majority of natural monoclonal antibodies are produced in non-human species (such as mice), and administering them to humans often results in human anti-mouse antibody (HAMA) responses[12]. This situation causes immunogenicity, swift clearance from the system, and diminished therapeutic effectiveness. Even when murine antibodies show strong specificity for their targets, their foreign nature hampers their clinical applicability.

Secondly, natural antibodies frequently display inadequate pharmacokinetics, characterized by a brief serum half-life and limited tissue penetration, especially in solid tumors or across biological barriers. This hampers their capacity to sustain therapeutic levels over extended periods. Additionally, their binding affinities might not be sufficiently robust for

certain use cases, particularly in cancer treatment or viral neutralization, where strong and specific interactions are essential[13]. Furthermore, natural antibodies lack modularity; they cannot be readily reformatted or combined with drugs, toxins, or other proteins for innovative therapeutic creations such as antibody-drug conjugates (ADCs) or bispecifics[14].

A further limitation is their inflexibility in modifying effector functions. Natural antibodies rely on standard Fc receptor interactions, which may not create optimal conditions for the desired immune responses such as antibody-dependent cell-mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). Without engineering, it's impossible to enhance or inhibit these functions. Lastly, the large-scale production of natural antibodies can be variable, especially when sourced from polyclonal serum or non-recombinant methods, resulting in inconsistencies from batch to batch and complicating reproducibility and quality control[15].

HISTORICAL EVOLUTION OF ANTIBODY ENGINEERING

HYBRIDOMA TECHNOLOGIES AND DAWN OF MONOCLONAL ANTIBODIES

The emergence of hybridoma technology represented a groundbreaking advancement in the fields of immunology and biotechnology. Georges Köhler and César Milstein introduced it in 1975; later, this innovation led to the generation of monoclonal antibodies (mAbs)-specific antibodies derived from an individual B-cell clone[16]. Before this development, antibody preparations were polyclonal, consisting of a mixture of antibodies with different specificities and affinities, which rendered them inconsistent for use in therapy or diagnostics.

Hybridoma technology consists of fusing B lymphocytes that produce antibodies (usually from immunized mice) with immortal myeloma cells (cancerous cells)[17]. The hybrid cells that are formed are known as "hybridomas," and they retain the beneficial characteristics of both parent cells- the ability to generate a specific antibody and the potential for unlimited proliferation in culture. These hybridomas are selected using HAT medium (hypoxanthine-aminopterin-thymidine) to ensure that only the fused cells survive and are subsequently screened to identify clones that produce the desired antibody. This innovation provided a sustainable and reliable source of antibodies with consistent specificity, paving the way for their use in diagnostics, treatments, and research. The first FDA-approved monoclonal antibody drug, muromonab-CD3 (OKT3), was launched in the market in 1986 to help prevent transplant rejection[18].

However, the initial monoclonal antibodies were produced from mice, resulting in immune responses in humans. This issue led to the development of chimeric, humanized, and fully human antibodies thanks to progress in antibody engineering. Nevertheless, hybridoma technology remains a key approach for producing antibodies, especially in preclinical studies and the initial phases of therapeutic development[19].

SHIFT TO RECOMBINANT AND FULLY HUMAN ANTIBODIES

The emergence of recombinant DNA technology represented a significant shift in the development of antibodies, overcoming several drawbacks linked to traditional murine monoclonal antibodies. Initially generated using hybridoma technology, these murine antibodies frequently induced robust immune responses in humans, resulting in human anti-mouse antibody (HAMA) reactions that diminished their efficacy and caused negative side effects. To address this issue, researchers started to genetically modify antibodies, culminating in the creation of chimeric and humanized antibodies, where murine variable regions were incorporated into human constant regions[20].

The subsequent significant advancement was the development of fully human antibodies, which largely eliminated concerns related to immunogenicity. This breakthrough was facilitated by phage display libraries and transgenic mice with human immunoglobulin gene loci. Innovations such as Humira (adalimumab), the first fully human monoclonal antibody approved by the FDA, showcased the clinical and commercial viability of recombinant antibody technologies[14]. Recombinant antibody technology also enabled refined control over various antibody characteristics, including binding affinity, specificity, and effector functions. In contrast to traditional approaches, recombinant strategies permit high-throughput screening, modular design, and swift optimization, leading to advancements like bispecific antibodies, antibody fragments (Fab, scFv), and antibody-drug conjugates (ADCs).

Furthermore, recombinant platforms offer greater scalability, reproducibility, and adherence to GMP standards, making them well-suited for industrial manufacturing. This transformation has radically altered the field of therapeutic antibody development, establishing fully human and recombinant antibodies as the prevailing standard for the treatment of cancers, autoimmune disorders, infectious diseases, and beyond[21].

From Monoclonal To Multifunctional: The Evolving Landscape Of Engineered Antibodies

TIMELINE OF KEY ADVANCES IN ANTIBODY ENGINEERING

1975 -The Invention of Hybridoma Technology: Georges Köhler and César Milstein developed the hybridoma method, which enables the ongoing production of monoclonal antibodies by immortalizing B cells[22].

Early 1980s -Transition of Monoclonals from Laboratory to Clinical Use: By 1980, patients with lymphocytic cancers began receiving monoclonal antibodies, with the first recorded therapeutic use taking place in 1982, a successful application of anti-idiotype antibodies for chemotherapy-resistant B-cell lymphoma[23].

1986 - The Initial FDA Approval of a Monoclonal Antibody: Muromonab-CD3 (OKT3) became the first monoclonal antibody authorized for clinical use, specifically aimed at preventing transplant rejection[23].

1984 to 1986 - Evolution of Chimeric and Humanized Antibodies: In 1984, chimeric antibodies were introduced by merging murine variable regions with human constant regions. In 1986, the first humanized antibodies were created by attaching murine complementary determining regions (CDRs) to human frameworks, substantially decreasing immunogenicity[24].

Late 1980s - The First Effective Humanized mAb: Campath-1H, is a humanized monoclonal antibody that targets CD52. It reached an important clinical milestone with its development in 1988[23].

1990s - Advancements in Phage Display and Engineered Antibody Fragments: Phage display technology emerged in the mid-1980s, enabling the selection of antibody fragments and single-chain variable fragments (scFvs) in vitro based on their binding properties. These display methods were crucial in producing fully human antibodies without the need for animal immunization[24].

1997 to 1998 - Progress in Therapeutics and the First mAb for Cancer: Rituximab (1997), the first chimeric antibody applied in cancer treatment (targeting CD20), received approval. Daclizumab (1997), the inaugural humanized monoclonal antibody, was approved for transplant rejection. Trastuzumab (Herceptin), targeting HER2, was sanctioned in 1998 for treating HER2-positive breast cancer[23].

2002 - The First Fully Human Antibody from Phage Display: Adalimumab (Humira), the initial fully human antibody developed via phage display, gained FDA approval for the treatment of rheumatoid arthritis[23].

2006 - The First Fully Human Antibody Created with Transgenic Mice: Panitumumab (Vectibix) became the foremost completely human antibody that was developed using transgenic mice. It was approved for the treatment of colorectal cancer[23].

TECHNIQUES FOR ANTIBODY ENGINEERING

PHAGE DISPLAY

Phage display is an impactful in vitro method that transformed the process of discovering and engineering antibodies. Originating from the work of George P. Smith in 1985, this technique allows for the exhibition of peptides or proteins, particularly antibody fragments, on the surface of bacteriophages, mainly the M13 filamentous phage. The essential idea is connecting genotype (DNA) to phenotype (protein), facilitating the selection of binders for specific targets through successive rounds of selection and amplification.

In phage display, a DNA sequence that encodes an antibody fragment (typically scFv or Fab) is integrated into a phage genome, leading to the expression and display of the protein on the phage coat protein (usually pIII or pVIII). A library with up to 10^9-10^{11} distinct variants can be created, producing a combinatorial diversity that far exceeds what is possible in vivo. Utilizing a method known as bio panning, the phage library is exposed to an antigen that is immobilized[25]. Phages that target the specific antigen are kept, while those that do not bind are discarded. The phages that have bound are subsequently eluted, amplified in E. coli, and put through additional rounds of panning to select for high-affinity binders. This approach, which emulates natural selection, allows for the generation of antibodies with high specificity and affinity for a wide range of antigens, such as toxins, cytokines, membrane proteins, or tumor markers.

Phage display presents several benefits compared to traditional hybridoma approaches. It eliminates the need for immunization. It is entirely performed in vitro, enabling selection against toxic or non-immunogenic targets, allowing for affinity maturation via targeted mutagenesis, and supporting the design of innovative antibody formats such as nanobodies, bispecific, and Fc-modified antibodies[5]. The method is still a key component of the antibody development pipelines of the biotech and pharmaceutical industries, having been instrumental in the creation of Adalimumab (Humira), the first entirely human monoclonal antibody to be approved by the FDA.

YEAST AND MAMMALIAN DISPLAY SYSTEM

Yeast Display

Yeast surface display emerged in the 1990s as a viable alternative to phage display, providing a eukaryotic environment conducive to proper protein folding, glycosylation, and disulfide bond formation-elements that are crucial for the functionality of antibodies and complex protein scaffolds. In this approach, antibody fragments (usually scFv or Fab) are genetically linked to Aga2p, a protein that attaches to the yeast cell wall through Aga1p. This construct is presented on the surface of Saccharomyces cerevisiae or Pichia pastoris. Unlike phage display, yeast display aids in directly quantifying the antigen binding through flow cytometry, enabling high-throughput and quantitative selection based on binding affinity and expression levels[26].

Allowing precise affinity maturation, facilitating eukaryotic post-translational modifications (PTMs), working with FACS (fluorescence-activated cell sorting), and permitting real-time sorting based on binding and expression are its advantages. Also, it is better suited for conformational epitopes and glycoproteins than prokaryotic systems[27]. Yeast display is extensively utilized for isolating high-affinity human antibodies, particularly when structural complexity or epitope specificity is crucial (e.g., antibodies targeting GPCRs or tumor antigens).

Mammalian Display

Mammalian display systems, including those utilizing HEK293 or CHO cells, constitute the most physiologically relevant methodology for displaying and screening antibodies. These systems closely replicate the native cellular environment of human proteins, encompassing accurate folding, glycosylation, and trafficking, which are essential for the development of therapeutic antibodies. In mammalian display, full-length antibodies or fragments are combined with transmembrane domains (such as PDGFR, CD8α) and anchored to the cell membrane[28]. Expression is generally managed by viral vectors (like lentivirus) or transient transfection. The surface display permits direct screening using FACS, akin to yeast display, but within a system that reflects therapeutic expression conditions.

Advantages of mammalian display are that it guarantees native-like post-translational modifications and glycosylation patterns, and it is capable of presenting full-length IgG, not merely fragments. This allows screening for functional binding, receptor internalization, or cell signaling and is ideal for examining antibodies that target membrane proteins and conformational antigens. Although more costly and slower than phage or yeast display, mammalian display is especially valuable in the later stages of antibody development, where functionality and manufacturability are of utmost importance[29].

SITE-DIRECTED MUTAGENESIS

Site-directed mutagenesis is a notable approach in molecular biology that is crucial for antibody engineering, allowing researchers to make precise, planned alterations to specific nucleotide sequences within antibody genes. This allows for changes to amino acid residues in the variable regions of antibodies, particularly within the complementarity-determining regions (CDRs), enhancing their antigen-binding affinity, specificity, and stability[30]. In therapeutic antibody development, site-directed mutagenesis aids in eliminating immunogenic epitopes, optimizing effector functions in the Fc region, and enhancing pharmacokinetics. Typically, this procedure utilizes polymerase chain reaction (PCR)-based techniques or oligonucleotide-directed synthesis to incorporate the intended mutations, followed by the expression and functional screening of the altered antibodies. By methodically investigating amino acid substitutions, researchers can elucidate structure-function relationships that inform the rational design of next-generation antibodies. This method has played a vital role in producing high-affinity humanized and fully human monoclonal antibodies, propelling advancements in diagnostics and targeted treatments for oncology, autoimmune diseases, and infectious diseases.

CRISPR/Cas9-Based Genetic Alteration in Mammalian Cells: CRISPR/Cas9-enhanced homology-directed mutagenesis (HDM) is an innovative method for large-scale antibody engineering in mammalian cells. It is an innovative technique utilizing CRISPR-HDR and degenerating the oligonucleotides for targeted mutagenesis within mammalian display systems, facilitating affinity maturation and comprehensive mutational scanning directly in the context of full-length IgG[31].

Targeted Libraries through Natural Diversity Mutagenesis: The use of degenerate codons for focused mutagenesis that mirrors natural diversity is complemented by the application of computational alanine-scanning to pinpoint suitable CDR sites in the Simple Affinity Maturation of Antibody Variable Domains through the Natural Diversity Mutagenesis technique. This approach accelerates the process of affinity maturation while preserving both specificity and stability[32].

Look-Through Mutagenesis (LTM) utilizing Combinatorial Libraries: A comprehensive technique aimed at significantly enhancing the affinity of antibodies through the use of combinatorial libraries. It presents the LTM strategy, which employs a selective collection of oligonucleotides to introduce representative changes throughout all six CDRs, facilitating the detection of substitutions that enhance affinity and producing variants with high affinity[33].

RIBOSOME AND mRNA DISPLAY

In vitro selection and evolution methods such as ribosome display and mRNA display work well in conjunction with site-directed mutagenesis to produce highly affinitized engineered antibodies[34]. In the ribosome display technique, an mRNA that encodes antibody fragments is translated in vitro in the absence of a stop codon, which results in the growing polypeptide being attached to its related mRNA via the ribosome. This stable complex (mRNA-ribosome-protein) facilitates a direct physical connection between phenotype and genotype, allowing for the iterative selection of variants with enhanced binding characteristics[35]. Combining ribosome display with focused site-directed mutagenesis in the complementarity-determining regions (CDRs) allows for the enhancement of libraries to achieve functional diversity while reducing unrelated mutations.

Conversely, mRNA display involves a covalent attachment between the antibody fragment and its mRNA using a puromycin linker, resulting in an even more robust genotype-phenotype linkage. This strategy supports exceptionally large library sizes (over 10^{13} variants), which is beneficial for examining mutation combinations produced through saturation or focused mutagenesis[36]. Both techniques overcome the challenges associated with host cell transformation efficiency and can be seamlessly integrated into affinity maturation workflows, where site-directed mutagenesis implements specific alterations, and display technologies quickly screen and enrich the most promising candidates[37]. Collectively, they create a complementary pipeline for the development of next-generation therapeutic antibodies characterized by greater specificity, stability, and affinity.

CRISPR APPLICATIONS IN ANTIBODY ENGINEERING

Site-Specific Antibody Conjugation via CRISPR/Cas9

A hybridoma platform engineered with CRISPR/Cas9 has introduced a Sortase (LPXTG) and Flag tag into the CH3 region of monoclonal antibodies, allowing for precise, site-specific attachment of cargo (such as drugs or labels), enhancing uniformity and maintaining antigen-binding functionality[38].

Engineering Constant Domains through CRISPR/HDR

To maintain specificity, hybridomas were modified through CRISPR-driven homology-directed repair (HDR) to generate Fab fragments, isotype-switched chimeric antibodies, and Fc-silent variants. This technique allows for the tailoring of antibody formats while preserving their functional characteristics[39].

High-Throughput Mutagenesis via CRISPR-HDM in Mammalian Cells

The Homology-Directed Mutagenesis (HDM) technique utilizes CRISPR/Cas9 HDR in mammalian cells in combination with degenerate-oligonucleotide libraries to create and evaluate variable libraries (like CDRH3) directly in complete IgG forms. When paired with next-generation sequencing, HDM enhances affinity maturation and allows for extensive mutational analysis on a large scale[31].

Whole-Variable Gene Cassette Integration in Hybridomas

CRISPR-Cas9 HDR was utilized to incorporate entire libraries of variable light (VL) and heavy (VH) chain genes into the genomes of hybridomas. This allowed for the surface expression, secretion, and thorough evaluation of a diverse array of antibody variants, including those exhibiting enhanced affinity in the picomolar range[40].

CRISPR-X for In Vitro Affinity Maturation

The CRISPR-X methodology utilizes a mutated deaminase linked to dCas9 to direct AID-induced somatic hypermutation at specific antibody loci, allowing for quick affinity maturation in mammalian cells within two mutation-selection cycles, simulating the natural immune selection process[41].

Modulating Antibody Effector Function via CRISPR-Mediated Glycosylation Editing

CRISPR/Cas9 was utilized to knock out the FUT8 gene (α1,6-fucosyltransferase) in CHO cells, resulting in antibodies with decreased Fc fucosylation and a notable increase in ADCC activity, highlighting the potential of CRISPR in engineering cell lines for enhanced therapeutic antibody quality[42].

Targeted Delivery of CRISPR/Cas via Antibody Conjugates

A recently created platform connected CRISPR/Cas nanocomplexes with monoclonal antibodies aimed at HER2, allowing precise delivery and gene editing in HER2-positive cancer cells in both laboratory settings

and living organisms, which led to the disruption of genes and inhibition of tumor growth[43].

TYPES OF ENGINEERED ANTIBODIES

CHIMERIC ANTIBODIES (MURINE VARIABLE + HUMAN CONSTANT REGIONS)

Chimeric and humanized antibodies mark significant advancements in the development of therapeutic antibody engineering, serving as a link between early murine monoclonal antibodies and the fully human antibodies currently in use.

Chimeric antibodies are engineered molecules that combine the antigen-binding variable regions of a non-human (usually mouse) monoclonal antibody with the constant regions of a human antibody. This structure preserves the specificity of the initial mouse antibody while significantly reducing the likelihood of immunogenic responses when given to humans[44]. A notable instance is rituximab, which was the first chimeric monoclonal antibody authorized by the FDA. It specifically targets CD20 found on B cells and is used for treating non-Hodgkin's lymphoma as well as certain autoimmune diseases[45]. Chimeric antibodies usually comprise approximately 65-70% human protein sequence and about 30-35% murine sequence, enhancing pharmacokinetics and effector functions relative to fully murine antibodies.

HUMANIZED ANTIBODIES (CDR GRAFTING INTO HUMAN FRAMEWORKS)

Humanized antibodies enhance this strategy by incorporating only the murine complementarity-determining regions (CDRs)-the specific segments that directly interact with the antigen-onto a human antibody structure. This approach, developed in the late 1980s, further decreases the mouse-derived content to under 10%, thus lowering the chances of triggering human anti-mouse antibody (HAMA) reactions while maintaining antigen specificity. A landmark instance of this is trastuzumab, a humanized antibody that targets HER2 in breast cancer treatment[46].

This review paper on engineered antibodies highlights the transition from chimeric to humanized antibodies as a vital engineering challenge-achieving a balance between antigen specificity, low immunogenicity, and optimal therapeutic effectiveness. These strategies have paved the way for creating fully human antibodies through methods such as phage display, transgenic animal technology, and CRISPR-based gene editing[47]. Additionally, chimeric and humanized antibodies continue to play a significant role today, particularly in the design of bispecific antibodies and antibody-drug conjugates, where modular antibody fragments are combined to create customized therapeutic functions[48].

FULLY HUMAN ANTIBODIES

Fully human antibodies signify a major breakthrough in therapeutic antibody development, addressing the immunogenicity challenges commonly linked to murine, chimeric, or humanized antibodies. These antibodies can be produced using either transgenic mouse platforms or phage display techniques.

Via Mice and Phage Display

In the transgenic mouse method, mice are genetically modified to possess human immunoglobulin gene loci, allowing them to create antibodies with completely human variable and constant regions when immunized with the target antigen. This approach preserves the innate in vivo affinity maturation and class switching processes, leading to high-affinity antibodies that have physiologically relevant structures[49]. Conversely, phage display technology is an entirely in vitro method that presents extensive libraries of human antibody fragments, including single-chain variable fragments (scFvs) or Fab fragments, on the surfaces of bacteriophages. These libraries are tested against the target antigen, and clones that exhibit the highest binding affinity are selected for additional optimization[50].

Both approaches have produced numerous therapeutics that have received clinical approval, such as adalimumab, the first fully human monoclonal antibody developed using phage display, and pembrolizumab, created through transgenic mice[51]. The advent of fully human antibodies has transformed biologics, offering safer, more effective treatments with a diminished risk of anti-drug antibody (ADA) responses, and has set the stage for next-generation antibody therapeutics that exhibit improved pharmacokinetics, specificity, and efficacy.

Fab, F(ab′) $_2$, AND scFv FRAGMENTS

Fab Fragment

It is made up of one light chain (VL + CL) linked by a disulfide bond to the variable (VH) and constant (CH1) regions of the heavy chain. This molecule is generated by the enzymatic cleavage of complete IgG using papain[52]. Its size is approximately 50 kDa, smaller than full IgG, which is about 150 kDa, allowing for enhanced tissue penetration. It retains its ability to bind to antigens but lacks the Fc region, which minimizes effector functions and reduces immunogenicity. Clinical success of this includes examples such as abciximab, ranibizumab, and certolizumab pegol,

which collectively represented around 49% of fragment-based clinical candidates before 1995[52].

F(ab′)₂ Fragment

It is created through pepsin digestion and consists of two Fab fragments linked by disulfide bonds in the hinge region, resulting in a bivalent fragment weighing about 110 kDa[53]. It exhibits greater avidity compared to monovalent Fab, enabling stronger binding to antigens. It is suited for scenarios where Fc-mediated actions are undesirable.

scFv (Single-Chain Variable Fragment)

scFv is the recombinant fusion of the variable domains of heavy (VH) and light (VL) chains connected by a flexible linker rich in glycine and serine (approximately 10-25 amino acids)[54]. It is small in size (about 25-30 kDa). Facilitates excellent tissue penetration and expression within bacterial systems and can be easily modified for improved affinity and stability, and is beneficial in bispecific applications, CAR-T designs, and diagnostic tools[53]. Drawbacks associated with it are that is susceptible to aggregation, has lower stability, and experiences faster clearance due to the absence of an Fc region. There may also be potential humoral immunogenicity if sourced from non-human origins[53].

BISPECIFIC ANTIBODIES (e.g., BiTEs, DARTs)

BiTEs (Bispecific T-cell Engagers)

BiTEs are composed of two single-chain variable fragments (scFvs) linked by a flexible peptide, allowing T-cell cytotoxicity to be directed toward cancer cells without needing MHC or co-stimulation. Blinatumomab, the first BiTE approved by the FDA, targets CD19 on B-cell malignancies and CD3 on T cells. It has shown impressive efficacy and outstanding therapeutic outcomes[55]. A comprehensive review of clinical trials emphasizes the efficacy of blinatumomab in managing relapsed or refractory acute lymphoblastic leukemia as well as non-Hodgkin's lymphoma, with manageable occurrences of cytokine release syndrome (CRS) and neurotoxic effects[56].

Despite the clinical difficulties linked to BiTE therapy, including a brief half-life that requires ongoing infusion and the possible dangers of cytokine release syndrome (CRS) and neurotoxicity, advancements in next-generation formats (such as half-life extending BiTEs) are being designed to improve safety and usability[57].



Figure 1: BiTE (Bispecific T cell Engagers)

DARTs (Dual Affinity Re Targeting)

DARTs are designed as disulfide-linked heterodimeric diabodies, allowing stable, bivalent binding to two distinct antigens. The structural design resembles natural IgG, enhancing stability, minimizing aggregation, and promoting better T-cell redirection compared to BiTEs in laboratory settings[58]. Clinical uses include flotetuzumab (CD3×CD123) for acute myeloid leukemia and MGD007 (CD3×GpA33) for colorectal cancer. Phase I trials indicate acceptable safety profiles and significant complete response rates. DART molecules have also demonstrated improved T-cell activation compared to BiTEs[59].



Figure 2: DART(Dual Affinity Re Targeting)

ANTIBODY DRUG CONJUGATES(ADC)

A new category of specialized cancer therapies called antibody-drug conjugates (ADCs) merges the powerful cytotoxic properties of chemotherapy drugs with the precise targeting capabilities of monoclonal antibodies. The development of ADCs involves three crucial components: a monoclonal antibody that identifies a tumor-associated antigen, a toxic payload, and a chemical linker that securely binds these two elements together[60]. After administration, the antibody specifically binds to its target antigen located on the surface of the cancer cell, which starts the receptor-mediated endocytosis of the ADC. Inside the cell, the linker is severed—either via enzymatic activity or

shifts in pH—liberating the cytotoxic drug straight into the tumor cell to induce apoptosis[61]. This targeted methodology enables ADCs to deliver extremely potent drugs, like auristatins, maytansinoids, or calicheamicin, at levels that would otherwise be unmanageable if given systemically, thereby enhancing therapeutic effectiveness while minimizing systemic toxicity[61].

Progress in ADC technology concentrates on refining antigen selection for tumor specificity, creating more stable and cleavable linkers to regulate drug release, and developing site-specific conjugation techniques to ensure consistent drug–antibody ratios (DARs) for reliable pharmacokinetics and safety profiles[62]. Numerous ADCs, including trastuzumab emtansine (T-DM1) for HER2-positive breast cancer and brentuximab vedotin for Hodgkin lymphoma, have already demonstrated clinical success, with many others in advanced stages of development aimed at both hematological cancers and solid tumors[63]. New strategies are incorporating ADCs with bispecific antibodies, immune checkpoint inhibitors, or innovative payload types to combat drug resistance and broaden their therapeutic range, establishing ADCs as one of the most promising approaches in contemporary oncology.

Clinical Examples and Payload Strategy

Trastuzumab Emtansine (T-DM1) incorporates a non-cleavable thioether linker, which allows its payload to be released solely through intracellular degradation within lysosomal compartments. Gemtuzumab Ozogamicin, recognized as the first FDA-approved ADC, employs a hydrazone cleavable linker that activates in acidic lysosomal settings, although it experienced issues with off-target toxicity[61]. Polatuzumab Vedotin (Polivy), an FDA-approved ADC that targets CD79b in cases of diffuse large B-cell lymphoma, utilizes a protease-sensitive linker, which facilitates the release of MMAE[64].

Fc-ENGINEERED AND GLYCOENGINEERED ANTIBODIES

Fc-engineered and glycoengineered antibodies are sophisticated modifications of therapeutic antibodies to improve their effectiveness, safety, and pharmacokinetic characteristics. The Fc (Fragment crystallizable) region of an antibody is crucial for employing immune effector functions such as antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and engagement with Fc gamma receptors (FcγRs) found on immune cells. Fc engineering consists of intentional alterations to the amino acid sequence in this region to enhance or adjust these effector functions. For instance, changes made in the Fc domain can boost binding affinity to activating Fcγ receptors (like FcγRIIIa), thereby augmenting ADCC activity, which is essential for cancer immunotherapy[65]. Antibodies that have undergone Fc engineering may also have an extended half-life due to improved binding to the neonatal Fc receptor (FcRn), allowing for sustained therapeutic levels in circulation. In addition to Fc engineering, glycoengineering modifies the carbohydrate structures (N-linked glycans) present on the Fc region, which significantly influence antibody stability and interactions with receptors. By altering glycosylation patterns-such as minimizing core fucose residues or changing sialylation, glycoengineered antibodies can show strengthened effector functions, particularly increased ADCC due to enhanced affinity for FcγRIIIa[66]. This strategy has been crucial in the creation of next-generation therapeutic antibodies that have superior clinical effectiveness and fewer side effects. Collectively, Fc and glycoengineering offer impactful methods to customize antibody functions to meet various clinical requirements, including those in oncology, autoimmune disorders, and infectious diseases.



Figure 3: Fc and Glycoengineered Antibody

NANOBODIES AND SINGLE-DOMAIN ANTIBODIES (sdAbs)

Nanobodies and single-domain antibodies (sdAbs) are a unique type of antibody fragment that are derived from heavy-chain-only antibodies present in camelids, such as camels, llamas, and alpacas, as well as certain species of cartilaginous fish[67]. Unlike conventional antibodies that consist of both heavy and light chains, these antibodies are formed from a single monomeric variable domain (VHH in camelids or VNAR in sharks) which retains full antigen-binding capabilities.

Their low molecular weight (around 12-15 kDa), exceptional stability, and ability to bind to cryptic or recessed epitopes that larger antibodies cannot reach enhance their importance in biomedical applications[68]. Nanobodies demonstrate exceptional thermal and chemical resilience, can be efficiently produced in microbial systems such as E. coli or yeast, and possess rapid tissue penetration abilities, making them suitable for therapeutic, diagnostic, and imaging applications. Their single-domain composition facilitates straightforward genetic modification for fusion with effector molecules, leading to the creation of multifunctional constructs such as bispecific antibodies, antibody-drug conjugates, or CAR-T targeting modules. Clinically, drugs based on nanobody-like caplacizumab, which is the first nanobody approved by both the FDA and EMA-have shown their therapeutic effectiveness in managing immune-mediated thrombotic thrombocytopenic purpura[69]. Additionally, their low immunogenicity, ease of manufacturing, and versatility position them as a promising area in advancing next-generation antibody engineering.

Structural Simplicity: Nanobodies do not have light chains and consist of a single monomeric variable antibody domain, fully retaining the ability to bind to antigens. Their miniature size and single-domain architecture enable them to reach epitopes that may be concealed or hard to access for conventional antibodies.

High Stability and Solubility: Their hydrophilic surface and a stable β-sheet core are of great importance. Nanobodies demonstrate exceptional thermostability and are resistant to proteolytic degradation, and remain soluble even under extreme pH or ionic conditions. This makes them particularly suitable for therapeutic and diagnostic applications in challenging environments, such as the gastrointestinal tract.

Ease of Genetic Manipulation and Expression: Due to their straightforward structure, nanobodies can be produced effortlessly in bacterial, yeast, and mammalian expression systems. Their compact genes facilitate quick engineering for fusion proteins, multimerization, or conjugation with drugs, enzymes, or toxins.

Efficient Tissue Penetration: Their small size allows for swift and deeper penetration into tissues, which is advantageous in the treatment of solid tumors or central nervous system disorders. However, this leads to a short serum half-life, often necessitating fusion with Fc regions, PEGylation, or albumin-binding domains to improve their circulation time.

Applications in Medicine and Biotechnology

Therapeutics: For instance, Caplacizumab is the first drug based on nanobody technology approved for treating thrombotic thrombocytopenic purpura.

Diagnostics: Nanobodies are employed as imaging agents for tumors, such as anti-HER2 nanobodies that are tagged with radionuclides.

Research Tools: They are utilized for intracellular targeting ("intrabodies"), as biosensors, and as crystallization chaperones in structural biology.

Engineering Versatility: Nanobodies can be linked together to create bispecific or multispecific antibodies, conjugated to toxins (like antibody-drug conjugates), or fused with Fc domains to restore effector functions. Their modular nature allows for various customizations for immune modulation or targeted therapy.

THERAPEUTIC APPLICATIONS

CANCER IMMUNOTHERAPY

Cancer immunotherapy, particularly with the use of immune checkpoint inhibitors, has revolutionized cancer treatment by leveraging the patient's immune system to recognize and eliminate tumor cells. Key immune checkpoints such as programmed death-1 (PD-1), its partner PD-L1, and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) are crucial in modulating immune tolerance and avoiding autoimmune reactions by inhibiting T cell activation[70]. However, cancer cells take advantage of these pathways by overproducing checkpoint ligands, which inhibit the cytotoxic T cell response and allow for immune evasion. Monoclonal antibodies that target these checkpoints, including anti-PD-1 (nivolumab, pembrolizumab), anti-PD-L1 (atezolizumab, durvalumab), and anti-CTLA-4 (ipilimumab), interrupt these inhibitory signals and revive T cell–mediated antitumor activities[71]. This treatment strategy has shown lasting responses in various cancers, including melanoma, non–small cell lung cancer, renal cell carcinoma, and Hodgkin lymphoma. Combination therapies, such PD-1/CTLA-4 inhibition, increase efficacy by addressing several immune-regulatory pathways at once, but they may also increase immune-related adverse effects[72]. Ongoing studies aim to address resistance mechanisms, discover predictive biomarkers, and combine checkpoint inhibitors with other therapeutic approaches like cancer vaccines, targeted therapies, and adoptive T cell transfer to enhance long-term patient outcomes.

AUTOIMMUNE DISORDERS

Autoimmune diseases like rheumatoid arthritis, inflammatory bowel disease, and psoriasis are frequently caused by unregulated immune reactions, which include an overproduction of pro-inflammatory cytokines such as tumour necrosis factor-alpha (TNF-α). Monoclonal antibodies known as anti-TNF antibodies, including infliximab, adalimumab, and golimumab, are specifically designed to attach to TNF-α, inhibiting its function and blocking its interaction with cell surface receptors TNFR1 and TNFR2. This blockage dampens downstream inflammatory signalling pathways, especially the activation of NF-κB, which leads to a reduction in immune cell recruitment, cytokine release, and tissue damage[73]. These biologic therapies can be classified as chimeric, humanized, or fully human based on their development methods, affecting factors like immunogenicity and how well patients tolerate them. While these medications are very effective in managing inflammation and stopping disease progression, prolonged usage may heighten the risk of infections, reactivate latent tuberculosis, and, in rare situations, lead to malignancies. Recent advancements in antibody engineering, including modifications to the Fc region and bispecific formats, aim to enhance selectivity, minimize side effects, and improve treatment outcomes for individuals with autoimmune diseases[74].

Anti-TNF agents successfully tackle complications that extend beyond the gastrointestinal tract, such as joint problems, skin issues, and liver disorders, demonstrating high response rates (for instance, an 80% improvement in Crohn's disease patients with skin or joint concerns). Adalimumab (Humira) is a fully human IgG1 monoclonal antibody that targets TNF, has a long half-life of around two weeks, exhibits low immunogenicity, and is approved by the FDA for a variety of conditions, including rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriatic arthritis, and juvenile arthritis, among others. Golimumab is also a fully human IgG1 monoclonal antibody, demonstrating a higher affinity for both soluble and transmembrane TNF compared to previous agents. It is utilized in conditions such as rheumatoid arthritis and ulcerative colitis, providing effective neutralization and an extended half-life[73].

Risks and Side Effects of Anti-TNF Therapy

Frequent side effects include reactions at the injection site, severe infections (such as tuberculosis and reactivation of hepatitis B), and uncommon immunologic conditions like drug-induced lupus or demyelinating diseases. Although the association with lymphoma is debated, it is important to exercise caution, particularly when using combination immunosuppression[75].

Autoimmune Paradoxes

Anti-TNF therapies can trigger autoimmune responses, resulting in conditions similar to lupus, interstitial lung diseases, autoimmune hepatitis, and even polymyositis or vasculitis. Instances of paradoxical psoriasis or sarcoidosis have also been reported, though they are rare[76].

INFECTIOUS DISEASES

Monoclonal antibodies have become essential treatments for infectious diseases due to their high specificity, neutralizing capacity, and ability to modulate the immune response. In cases of Ebola virus disease, antibodies like mAb114 and REGN-EB3 have shown notable improvements in survival rates by binding to viral glycoproteins and blocking the entry of the virus into host cells, which resulted in their emergency authorization during outbreaks[77]. For COVID-19, the rapid identification of antibodies using techniques such as phage display, transgenic mice, and B cell cloning has produced neutralizing antibodies like REGN-COV2 (casirivimab/imdevimab), sotrovimab, and bebtelovimab, which inhibit the interaction between the SARS-CoV-2 spike protein and ACE2[78].

In addition to directly neutralizing the virus, antibodies can activate Fc-mediated effector functions to boost viral clearance. Although their effectiveness is evident, challenges persist, including the potential for viral escape mutations, high production costs, and the necessity for broadly neutralizing antibodies to tackle antigenic drift and the emergence of variants. Current research is concentrating on the development of antibodies with longer half-lives, bispecific constructs aimed at targeting conserved epitopes, and combination therapies to enhance resistance to viral evolution.

Monoclonal antibodies aimed at the RBD of the spike protein effectively inhibit viral entry by blocking the binding of the ACE2 receptor. Clinical studies indicated that bamlanivimab, casirivimab/imdevimab, and sotrovimab significantly lowered viral loads and prevented the progression to severe illness, particularly when given early. Combination therapies have shown greater resilience against emerging variants, but challenges remain regarding cost, logistics, and the potential for variant evasion. Evusheld (tixagevimab + cilgavimab) is approved for pre-exposure prophylaxis in individuals with weakened immune systems, demonstrating significant effectiveness in preventing symptomatic COVID-19 in those who are less

responsive to vaccines. An innovative strategy utilizing VHH (nanobody)-based antibodies, sourced from llamas, targets the spike's S2 subunit-an area that is less susceptible to mutations. These nanobodies have shown strong resistance to viral changes and the potential for scaling, providing optimism for long-lasting, widespread protection[79].

NEURODEGENERATIVE AND CARDIOVASCULAR CONDITIONS

Monoclonal antibodies (mAbs) are increasingly viewed as promising therapies for neurodegenerative and cardiovascular disorders due to their precise targeting, ability to act on pathological proteins, and potential to alter disease progression. In neurodegenerative conditions like Alzheimer's disease (AD), antibodies targeting amyloid-β (such as aducanumab and lecanemab) aim to diminish plaque buildup, safeguard neurons from damage, and slow cognitive decline[80]. Similarly, for Parkinson's disease, mAbs that focus on α-synuclein are being developed to curb the aggregation and transmission of harmful protein forms[81]. In cardiovascular ailments, therapeutic antibodies can target pro-inflammatory cytokines, adhesion molecules, or lipid metabolism regulators to help alleviate inflammation, thwart plaque formation, and decelerate atherosclerosis progression. For example, PCSK9 inhibitors (evolocumab and alirocumab) significantly lower low-density lipoprotein cholesterol (LDL-C) levels, subsequently reducing the risk of heart attacks and strokes. Additionally, antibodies aimed at IL-1β (canakinumab) have shown effectiveness in lowering cardiovascular incidents by diminishing chronic vascular inflammation[82]. Current clinical trials are evaluating the efficacy, dosing strategies, and safety of these treatments, aiming to expand their application in various chronic neurodegenerative and heart diseases.

DIAGNOSTIC AND RESEARCH APPLICATIONS

USE IN IMMUNOASSAYS (ELISA, WESTERN BLOT, FLOW CYTOMETRY)

Antibodies are crucial components in immunoassays like ELISA, Western blotting, and flow cytometry, acting as specialized tools for the detection and quantification of specific antigens. In ELISA (enzyme-linked immunosorbent assay), antibodies are either fixed onto a solid surface or function as detection agents to capture and bind targeted antigens, followed by enzymatic reactions that generate signals for accurate quantification, making this technique essential for diagnostics, vaccine creation, and biomarker identification[83]. In Western blotting, antibodies offer high specificity for detecting proteins. Primary antibodies attach to the target protein that has been separated through gel electrophoresis and subsequently transferred to a membrane, while secondary antibodies tagged with enzymes or fluorophores facilitate visualization[84].

In flow cytometry, fluorescently labelled antibodies adhere to surface markers on cells or intracellular targets, allowing for the multiparametric analysis of diverse cell populations at the single-cell level, which is vital for immunophenotyping, cancer detection, and immune monitoring. Innovations in antibody engineering, including the creation of recombinant monoclonal antibodies, nanobodies, and Fc-modified variants, have enhanced assay sensitivity, minimized background interference, and improved reproducibility, allowing for wider applications in clinical diagnostics, research, and high-throughput screening systems[85]. The diagnostic effectiveness of ELISA, Western blot, and flow cytometry was assessed using actual sera from tularemia patients. Both Western blot and flow cytometry demonstrated a sensitivity and specificity of 100%, which was closely approximated by ELISA at 98%, indicating their complementary usefulness[86].

BIOSENSORS AND IMAGING

Antibody-Based Biosensors (Immunosensors)

Immunosensors are analytical tools that combine a biological recognition component-namely an antibody or antigen-with a physicochemical transducer to accurately detect specific target analytes. In these devices, the interaction between antibodies and antigens is transformed into a quantifiable signal, typically utilizing optical, electrochemical, piezoelectric, or surface plasmon resonance (SPR) techniques. Antibodies are crucial for capturing the target molecules due to their excellent specificity and affinity, while engineered antibodies, such as nanobodies and recombinant fragments, are progressively utilized to enhance stability, binding kinetics, and simplicity of immobilization. Immunosensors find extensive use in medical diagnostics, environmental monitoring, food safety assessments, and biothreat detection. For example, SPR chips that are functionalized with antibodies enable real-time biomarker monitoring without the need for labels, whereas electrochemical immunosensors provide a cost-effective and portable detection option ideal for point-of-care applications.

Developments in nanomaterials, including gold nanoparticles, carbon nanotubes, and graphene, have markedly improved the sensitivity of immunosensors

by facilitating better electron transfer rates or expanding the effective surface area for antibody attachment. Furthermore, integrating immunosensors with microfluidic technology has allowed for quick, multiplexed detection from minimal sample quantities, making them effective instruments for early disease diagnosis and real-time monitoring. Electrochemical immunosensors have become increasingly important as versatile and sensitive devices for point-of-care applications. By improving electrode conductivity and enabling antibody immobilization, the use of nanomaterials such as metal nanoparticles, carbon nanotubes, and graphene dramatically increases sensitivity and lowers detection limits.[87].

When screen-printed electrodes (SPEs) are modified with antibodies, they provide a portable and durable platform for the quick detection of biomarkers, including COVID-19 antigens, making them exceptionally well-suited for clinical diagnostics and on-site testing[88]. The combination of antibodies and inorganic nanomaterials in dual system designs (like using nanocarriers or labels) increases electrochemical signals and improves the sensitivity and reproducibility of immunosensors-essential aspects for point-of-care usage[89]. Homogeneous immunosensors, particularly those utilizing fluorescent or bioluminescent antibodies, enable swift and highly sensitive detection without the need for wash steps-thereby simplifying diagnostics while maintaining cost-effectiveness and ease of use[90].

Antibody-Based Imaging Techniques

ImmunoPET integrates antibodies with positron-emitting markers to facilitate non-invasive, quantitative imaging of tumour antigen expression throughout the body. This technology supports patient selection, determines dosing methods, and monitors treatment efficacy-linking diagnostics to therapeutic approaches[91]. Engineered antibody fragments (such as minibodies, diabodies, and scFv-Fc constructs) have been created to improve pharmacokinetics, allowing for imaging to be performed on the same or following day with high contrast-addressing the limitations of traditional full-length antibodies in immuno PET[92].

Near Infra-Red (NIR) fluorescently labelled antibodies (like IRDye800CW-nimotuzumab) provide the capability for real-time, high-resolution imaging, including multicolour and [1]intraoperative visualization, which enhances surgical precision and tumour identification. A NIR-II probe utilizing cadherin 17 nanobodies conjugated with IRDye800CW is presented, specifically designed to target colorectal cancer. This imaging agent provides enhanced resolution, allowing for accurate tumour removal and the efficient administration of immunotoxins during surgical procedures[93].

COMPANION DIAGNOSTICS

Certain in vitro tests or imaging methods known as companion diagnostics (CDx) were created to determine whether patients are most likely to benefit from or be at risk of adverse reactions to specific treatments, particularly targeted medicines.. In the realm of antibody-based therapies, CDx is vital for facilitating personalized medicine by ensuring that the appropriate patient receives the appropriate medication at the correct dosage. These diagnostics usually identify predictive biomarkers such as levels of protein expression, genetic alterations, or specific antigens on cell surfaces to inform treatment choices. For instance, assessing HER2 overexpression with methods like immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) is crucial before administering trastuzumab for HER2-positive breast cancer[94].

Likewise, assays for PD-L1 expression help determine the suitability for checkpoint inhibitor therapies, such as pembrolizumab. Incorporating CDx into clinical settings eliminates guesswork in prescribing, enhances treatment effectiveness, reduces unnecessary side effects, and optimizes healthcare resources. Progress in technologies like next-generation sequencing (NGS), multiplex immunoassays, and antibody-based biosensors is further improving the sensitivity, specificity, and efficiency of CDx. Regulatory bodies, including the FDA, frequently require CDx approval to accompany new targeted therapies, highlighting their essential function in precision oncology, autoimmune disorder treatment, and management of infectious diseases[95].

CHALLENGES AND LIMITATIONS

IMMUNOGENICITY OF NON-HUMAN ANTIBODIES

HAMA: Human Anti-Mouse Antibody Response:

The application of murine monoclonal antibodies (mAbs) often triggers the generation of Human Anti-Mouse Antibodies (HAMA) in patients, potentially leading to allergic responses, quicker elimination from the body, reduced therapeutic efficacy, and altered pharmacokinetics.

Engineering Strategies to Reduce Immunogenicity:

Various antibody formats have been engineered to lessen immunogenicity. Chimeric Antibodies substitute non-human constant regions with human ones (approximately 60-70% human), which significantly reduces HAMA responses, although they can still elicit Human Anti-Chimeric Antibodies (HACA).

Humanized antibodies reduce their immunogenic potential by integrating complementarity-determining regions (CDRs) from non-human antibodies into human framework regions. This technique produces antibodies that are more than 80% human, yet there is still a possibility of anti-idiotypic responses due to the presence of non-human CDR sequences[96].

Fully Human Antibodies, created through phage display or transgenic techniques, entirely eliminate non-human elements. However, immunogenic responses can still occur, often linked to particular CDR residues or post-translational changes such as glycosylation.

Persistence of Immunogenic Risk in Humanized and Fully Human Antibodies: Even these sophisticated formats are not free from immunological risks. CDR regions are key immunogenic hotspots. Modifying one or two amino acids in an epitope-bearing CDR region can considerably lower immunogenicity while maintaining functional activity[97]. Other immunogenic factors encompass aggregation, variations in glycoforms, and sequence polymorphisms. Antibodies produced in clinical-grade host systems (e.g., CHO cells) may possess minor physicochemical variations that can provoke immune reactions[98].

Limitations of Non-Human Models for Predicting Human Immunogenicity: Immunogenic reactions in non-human primates (NHPs) do not consistently forecast human responses. Research has indicated that only 59% of the time do antibody responses align between NHPs and humans-underscoring that human immunogenicity exhibits a unique and unpredictable pattern[99].

Advanced Humanization Techniques: New computational approaches, such as generative modelling and humanness scoring, aim to refine sequences to minimize immunogenicity while preserving binding strength and developability. However, the relationship between computational "humanness" and actual reductions in anti-drug antibodies (ADA) is inconsistent and heavily influenced by context.

COST AND COMPLEXITY OF PRODUCTION

Cost of Goods (COGs): Initially, the production of monoclonal antibodies (mAbs) cost $300 per gram for the drug substance, which decreased to $100/g as process efficiencies improved. In optimal high-throughput facilities capable of processing 10 tons per year, COGs can fall to about $20/g. With titers of 5 g/L, the manufacturing costs for the drug substance drop significantly-from $124/g to $16/g, while the average cost for vial fill-finish is around $10[100].

Capital Expenditure (CAPEX): The investment required to construct a conventional mAb manufacturing facility with a capacity of approximately 3.4 tons per year is roughly $540 million. In contrast, modern continuous manufacturing systems can lower these costs to about $135 million by utilizing smaller, single-use systems.

Operational Complexity and Cost Drivers: The process of development and manufacturing typically accounts for 13-17% of a drug's total pre-approval research and development budget, often necessitating an investment of $60-70 million just to advance to late-stage trials. In continuous production facilities, the primary contributors to annual operational costs are raw materials, maintenance of infrastructure, and consumables, with media representing about 27% of the cost per gram of mAb[101].

Process Efficiency and Scale Impact: In the upstream (cell culture) stage, costs decrease significantly with higher titers; even small increases in yield can result in substantial cost benefits due to economies of scale. In the early stages of production, downstream materials, such as chromatography resins, are a significant cost factor. However, at scale, the recurring use of resins greatly reduces costs per cycle.

Technology Trends: Batch vs Continuous Manufacturing: Conventional stainless-steel batch reactors require considerable infrastructure investment and entail lengthy holding periods. Shifting to continuous (fully integrated) manufacturing, which includes single-use equipment, streamlined media, and multi-column chromatography, led to a cost reduction of up to 35%, with certain platforms aiming for production costs between $40 and $100/g[101].

Real-World Cost and Margin Gaps: Even with COG reductions to the range of tens of dollars per gram, market prices for mAbs often soar to between $2,000 and $100,000/g, influenced by packaging, distribution, and value-based pricing strategies. Industry insiders emphasize that the complexities involved are cell culture entail costly media and prolonged timelines, purification processes are resource-intensive, and regulatory-quality testing presents significant cost and time challenges[2].

STABILITY AND SOLUBILITY OF MONOCLONAL ANTIBODIES

Stability

Stability in therapeutic monoclonal antibodies pertains to their structural reliability and functional activity over time throughout production, storage,

transportation, and in vivo application. Various factors can influence this stability, which leads to chemical and physical instability. Chemical instability occurs due to deamidation (conversion of Asn to Asp), oxidation (particularly affecting Met and Trp residues), isomerization, and glycation.

Physical instability happens because of aggregation (formation of dimers or oligomers), fragmentation (notably occurring at hinge regions), and denaturation under adverse conditions (such as pH, temperature, or freeze-thaw cycles). Aggregation is a significant concern as it can lead to immunogenic responses and diminish therapeutic effectiveness. Strategies to enhance stability include protein engineering (e.g., implementing stabilizing mutations), refined glycosylation patterns, lyophilization (freeze-drying process), and utilization of stabilizing excipients (such as sugars, amino acids, surfactants)

Solubility

Solubility refers to the capacity of mAbs to stay dissolved at elevated concentrations (≥100 mg/mL) without experiencing precipitation or aggregation. Issues related to solubility include a high isoelectric point (pI) resulting in electrostatic repulsion, hydrophobic surface areas that encourage self-association, and aggregation occurring during concentration, formulation, or storage.

Factors influencing solubility comprise net charge at the pH of the formulation, hydrophobic interactions among complementarity-determining regions (CDRs), and intrinsic sequence vulnerabilities within the variable domains. Strategies to improve solubility involve optimizing sequences (e.g., decreasing surface hydrophobicity), adjusting pH and ionic strength, and incorporating excipients like arginine, histidine, or polysorbates[102].

ANTIBODY DELIVERY AND PHARMACOKINETICS

The pharmacokinetics of monoclonal antibodies (mAbs) fundamentally differ from those of small-molecule drugs due to their larger molecular weight, complex structures, and unique interactions with biological systems.

One important component is target-mediated drug disposition (TMDD), a nonlinear pharmacokinetic phenomena in which the rates of clearance of mAbs are significantly impacted by their strong binding to their pharmacological targets, which are frequently either soluble or membrane-bound antigens.. At lower concentrations, the binding of the target and the subsequent processes of internalization or degradation can primarily dictate elimination, resulting in increased clearance; however, at higher concentrations, the targets become saturated, and the clearance process transitions to a slower, nonspecific catabolism[103].

Another significant mechanism involves the recycling mediated by the neonatal Fc receptor (FcRn), which enhances the half-life of mAbs. FcRn attaches to the Fc region of IgG antibodies within acidic endosomal compartments, shielding them from being degraded in lysosomes and allowing for their recycling back into circulation at a physiological pH. This mechanism enables IgG-based therapies to achieve extended periods of systemic exposure, with half-lives that often surpass two weeks[104]. The relationship between TMDD and FcRn recycling plays an important role in developing dosing strategies, optimizing therapeutic windows, and anticipating variability in patient responses. Additionally, factors like glycosylation patterns, immunogenicity, and the state of the disease can further influence mAb pharmacokinetics, highlighting the necessity for a mechanistic understanding in the development of antibody drugs.

FUTURE PROSPECTS

ARTIFICIAL INTELLIGENCE IN ANTIBODY DESIGN

Artificial intelligence (AI) is transforming the field of antibody design by facilitating quick, precise, and economical predictions of antibody structures, binding affinities, and profiles for developability. Machine learning (ML) techniques, especially deep learning models like AlphaFold2 and those for protein-ligand interactions, enable the in-silico generation and refinement of antibody candidates that exhibit both high specificity and low immunogenicity[105]. AI-based tools combine extensive datasets from phage display, single-cell sequencing, and structural biology to forecast the conformations of complementarity-determining regions (CDRs), detect possible off-target impacts, and modify Fc or glycan components for enhanced pharmacokinetics.

In addition, generative AI methodologies can create completely new antibodies that extend beyond natural repertoires, thereby speeding up the process from hit identification to lead optimization. When paired with cloud-based solutions, AI systems are increasingly utilized for virtual screenings, multi-objective optimizations (considering binding, stability, and solubility), and directing experimental validation, thus changing conventional trial-and-error methods into predictive, data-informed workflows in the development of antibody therapeutics. Generative frameworks like RFdiffusion, Protein BERT, and Protein MPNN are utilized for the design and

enhancement of antibodies, encompassing tools for structure prediction and CDR generation, such as IgFold and DiffAb, with the goal of combining sequence and structural design[105].

SYNTHETIC BIOLOGY AND MODULAR ANTIBODY PLATFORMS

Synthetic biology has transformed antibody engineering by facilitating the deliberate design, enhancement, and modular assembly of antibody molecules for a variety of uses. Rather than depending exclusively on natural immune mechanisms, synthetic methods make it possible to create customized antibodies with particular functions, structures, or delivery characteristics[106].

Synthetic Biology in Antibody Design:

Synthetic biology utilizes genetic circuits, synthetic promoters, codon optimization, and synthetic gene assembly to modify cells (such as E. coli, CHO, or yeast) for effective antibody production and functional adjustment. Key techniques comprise the following:

De novo gene synthesis: Allows for the creation of custom antibody sequences without relying on natural templates.

Synthetic antibody libraries: Extensive, varied collections of entirely synthetic antibodies created using designed frameworks and randomized CDRs.

DNA assembly techniques (such as Gibson Assembly, Golden Gate): For the modular construction of antibody genes.

Modular Antibody Platforms: Modular platforms utilize interchangeable domains or "building blocks" to develop antibodies with innovative formats or functions:

scFv, Fab, and F(ab') $_2$ **modules**: Facilitate engineering and targeting.

Multispecific or bispecific formats (for example, BiTEs, DARTs): Merge two or more antigen-recognition sites.

Linker peptides: Modular linkers can adjust spacing and orientation to enhance stability or activity.

Plug-and-play formats: Enable fusion with toxins (ADC), enzymes, or signalling domains.

Applications include targeted cancer treatment, synthetic immune circuits (CARs, switchable antibodies), biosensors, and gene delivery.

PERSONALIZED ANTIBODY

Personalized antibodies are custom-designed monoclonal or recombinant antibodies tailored to the specific disease characteristics of a patient, which may include tumour antigens, immune environment, or genetic makeup. In contrast to standard, ready-to-use antibodies, these therapeutic solutions are crafted for precision medicine, aiming for optimal effectiveness while minimizing off-target reactions.

Principal Methods:

Neoantigen-targeted antibodies: These are derived from mutations specific to the patient's tumour. This approach involves tumour exome sequencing and the computational prediction of neoantigens. It is applied in both solid tumours and hematologic cancers[107].

Autologous B-cell screening: This method isolates and sequences B-cells from patients, such as those that are effectively combating infections or cancer. It is utilized for identifying potent neutralizing antibodies, such as those for COVID-19 and HIV.

Phage/Yeast display utilizing patient samples: Personalized antibody libraries are generated using immunoglobulin genes obtained from patients. This allows for the identification of high-affinity, specific antibodies.

CRISPR or base editing for antibody modification: Specific modifications are introduced into antibodies derived from patients or human frameworks. These adjustments refine the binding affinity, half-life, or effector functions.

AI-assisted antibody modelling: This approach predicts the best paratope-epitope interactions tailored to the patient's unique antigen. It can incorporate omics data, including proteomics or single-cell RNA sequencing.

mRNA-encoded antibody therapeutics

mRNA-based antibody therapeutics represent a new category of biologics that merge the precision of monoclonal antibodies with the adaptability of messenger RNA (mRNA) delivery systems. Rather than producing antibodies in a laboratory setting and administering them directly, this method involves introducing synthetic mRNA sequences that code for the desired antibody into the patient's cells, usually through lipid nanoparticle (LNP) carriers. Upon entering the cytoplasm, the patient's translational machinery generates the functional antibody in vivo, enabling rapid, localized, and transient production. This strategy eliminates the intricate, lengthy, and expensive cell culture processes traditionally employed in antibody production, allowing for quicker responses to emerging health threats such as viral outbreaks or swiftly changing cancer antigens.

Furthermore, mRNA platforms can be swiftly reconfigured to instruct the production of various antibody sequences, facilitating the creation of personalized or "on-demand" therapies tailored to an individual's genetic or immunological characteristics.

In clinical settings, mRNA-derived antibodies have been investigated for use in preventing infectious diseases (for instance, neutralizing antibodies targeting SARS-CoV-2, influenza, and the Zika virus), treating cancers (such as bispecific T-cell engagers aimed at tumour antigens), and managing autoimmune disorders[108].

Although initial research has demonstrated promising pharmacokinetics and effectiveness, there are still challenges to address-such as enhancing mRNA stability, controlling the duration of expression, reducing innate immune responses, and tackling potential immunogenicity issues associated with both the mRNA and the produced antibody. Nevertheless, with progress in LNP formulation, codon optimization, and self-amplifying RNA technologies, mRNA-encoded antibody therapeutics are set to become a flexible resource in the next wave of precision medicine, providing rapid scalability, adaptability, and potential cost benefits compared to traditional antibody production methods[109].

EMPHASIS ON INTERDISCIPLINARY INTEGRATION

Synthetic biology offers modular biological elements (such as genetic circuits and optimized host cells) for the regulated production and functionality of antibodies. The combination of AI and automation accelerates the design-build-test-learn cycles, making them quicker and more predictive. For example, synthetic circuits in CHO or HEK293 cells can be precisely adjusted using AI-based optimization to improve transcription, protein folding, glycosylation, and secretion pathways.

The combination of deep sequencing of antibody repertoires and machine learning enhances the identification of high-affinity, stable antibody candidates. AI algorithms can reveal sequence–function relationships and forecast structurally stable synthetic antibodies, significantly speeding up the design process[110]. The integration of nanotechnology introduces advanced methods where antibody-based nanoparticles can transport genetic materials, reprogram immune cells on-site, or act as intelligent delivery systems (such as liposomes and inorganic nanoparticles with imaging features). These systems can be targeted, modular, and co-engineered with antibodies to improve specificity[111].

Utilizing principles from systems biology, scientists develop quantitative, multiscale models of cells to inform synthetic biology designs. Comprehensive computational tools assist in predicting gene-circuit behaviour, minimizing the need for trial-and-error in laboratory experiments. This approach fosters a systems-level perspective of antibody production and functionality. The intersection of these fields illustrates the concept of “bio convergence,” where biology, computation, engineering, and nanotechnology come together to address complexity. In the field of antibody science, this multidisciplinary collaboration allows for the efficient, precise, and scalable advancement of therapeutic platforms.

ENCOURAGEMENT FOR TRANSLATIONAL RESEARCH AND INNOVATION

Promoting translational research and innovation in antibody therapeutics is essential for speeding up the process of moving discoveries from the lab to clinical settings. This requires encouraging cooperation among academic researchers, clinicians, biotech firms, and regulatory agencies to connect basic science with patient treatment. Translational research prioritizes the enhancement of antibody design, engineering, and manufacturing while also incorporating feedback from clinical practice to improve therapeutic methods. Innovations arise from progress in structural biology, artificial intelligence, high-throughput screening, and synthetic biology, allowing for the development of antibodies with improved specificity, effectiveness, and safety profiles. The creation of trastuzumab (Herceptin®) and bevacizumab (Avastin®) stands as significant examples of translational antibody research, showcasing how initial molecular findings resulted in successful cancer treatments through a series of validation phases[112].

Moreover, translational initiatives gain from robust interdisciplinary strategies that bring together immunology, bioinformatics, nanotechnology, and pharmaceutical sciences, ultimately shortening development timelines and facilitating the quicker delivery of new, life-saving antibody treatments to patients. Investment in translational infrastructures, along with accommodating regulatory processes, guarantees that scientific advancements are not limited to academic papers but are instead converted into useful and transformative therapeutic solutions.

REFERENCES:

1. Gruell, H., et al., *Antibody-mediated neutralization of SARS-CoV-2.* Immunity, 2022. **55**(6): p. 925-944.
2. Chen, X., O. Schneewind, and D. Missiakas, *Engineered human antibodies for the opsonization and killing of Staphylococcus aureus.* Proc Natl Acad Sci U S A, 2022. **119**(4).

3. Ovcinnikovs, V., et al., *Enhancing complement activation by therapeutic anti-tumor antibodies: Mechanisms, strategies, and engineering approaches.* Semin Immunol, 2025. **77**: p. 101922.
4. Nigro, C.L., et al., *NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives.* Annals of Translational Medicine, 2019. **7**(5): p. 105.
5. Nagano, K. and Y. Tsutsumi, *Phage Display Technology as a Powerful Platform for Antibody Drug Discovery.* Viruses, 2021. **13**(2).
6. Jakobovits, A., *Production of fully human antibodies by transgenic mice.* Curr Opin Biotechnol, 1995. **6**(5): p. 561-6.
7. Damelang, T., et al., *Impact of structural modifications of IgG antibodies on effector functions.* Frontiers in Immunology, 2024. **14**.
8. Lobner, E., et al., *Engineered IgG1-Fc--one fragment to bind them all.* Immunol Rev, 2016. **270**(1): p. 113-31.
9. Mariuzza, R.A., S.E. Phillips, and R.J. Poljak, *The structural basis of antigen-antibody recognition.* Annu Rev Biophys Biophys Chem, 1987. **16**: p. 139-59.
10. Abdeldaim, D.T. and K. Schindowski, *Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions.* Pharmaceutics, 2023. **15**(10): p. 2402.
11. Saxena, A. and D. Wu, *Advances in Therapeutic Fc Engineering – Modulation of IgG-Associated Effector Functions and Serum Half-life.* Frontiers in Immunology, 2016. **7**.
12. Presta, L.G., *Engineering of therapeutic antibodies to minimize immunogenicity and optimize function.* Adv Drug Deliv Rev, 2006. **58**(5-6): p. 640-56.
13. Iznaga-Escobar, N., A.K. Mishra, and R. Perez-Rodriguez, *Factors affecting pharmacokinetics of monoclonal antibodies: A review article.* Methods Find Exp Clin Pharmacol, 2004. **26**(2): p. 123-7.
14. Foltz, I.N., M. Karow, and S.M. Wasserman, *Evolution and Emergence of Therapeutic Monoclonal Antibodies.* Circulation, 2013. **127**(22): p. 2222-2230.
15. Al Ojaimi, Y., et al., *Therapeutic antibodies - natural and pathological barriers and strategies to overcome them.* Pharmacol Ther, 2022. **233**: p. 108022.
16. Ribatti, D., *From the discovery of monoclonal antibodies to their therapeutic application: An historical reappraisal.* Immunology Letters, 2014. **161**(1): p. 96-99.
17. Moraes, J.Z., et al., *Hybridoma technology: is it still useful?* Current Research in Immunology, 2021. **2**: p. 32-40.
18. Todd, P.A. and R.N. Brogden, *Muromonab CD3. A review of its pharmacology and therapeutic potential.* Drugs, 1989. **37**(6): p. 871-99.
19. Wilde, M.I. and K.L. Goa, *Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection.* Drugs, 1996. **51**(5): p. 865-94.
20. Bowers, P.M., et al., *Humanization of antibodies using heavy chain complementarity-determining region 3 grafting coupled with in vitro somatic hypermutation.* J Biol Chem, 2013. **288**(11): p. 7688-7696.
21. Hsieh, Y.-C., et al., *A universal in silico V(D)J recombination strategy for developing humanized monoclonal antibodies.* Journal of Nanobiotechnology, 2022. **20**(1).
22. Wang, Z., et al., *Development of therapeutic antibodies for the treatment of diseases.* Mol Biomed, 2022. **3**(1): p. 35.
23. Araki, K. and R. Maeda, *A Brief Chronicle of Antibody Research and Technological Advances.* Antibodies, 2024. **13**(4): p. 90.
24. Pucca, M.B., et al., *History of Envenoming Therapy and Current Perspectives.* Front Immunol, 2019. **10**: p. 1598.
25. Almagro, J.C., et al., *Phage Display Libraries for Antibody Therapeutic Discovery and Development.* Antibodies (Basel), 2019. **8**(3).
26. Könning, D. and H. Kolmar, *Beyond antibody engineering: directed evolution of alternative binding scaffolds and enzymes using yeast surface display.* Microbial Cell Factories, 2018. **17**(1).
27. Zahradník, J., et al., *A Protein-Engineered, Enhanced Yeast Display Platform for Rapid Evolution of Challenging Targets.* ACS Synthetic Biology, 2021. **10**(12): p. 3445-3460.
28. Zhou, C., et al., *Development of a novel mammalian cell surface antibody display platform.* MAbs, 2010. **2**(5): p. 508-18.
29. Valldorf, B., et al., *Antibody display technologies: selecting the cream of the crop.*

Biological Chemistry, 2022. **403**(5-6): p. 455-477.
30. Kim, H.Y., A. Stojadinovic, and M.J. Izadjoo, *Affinity maturation of monoclonal antibodies by multi-site-directed mutagenesis.* Methods Mol Biol, 2014. **1131**: p. 407-20.
31. Mason, D.M., et al., *High-throughput antibody engineering in mammalian cells by CRISPR/Cas9-mediated homology-directed mutagenesis.* Nucleic Acids Res, 2018. **46**(14): p. 7436-7449.
32. Tiller, K.E., et al., *Facile Affinity Maturation of Antibody Variable Domains Using Natural Diversity Mutagenesis.* Front Immunol, 2017. **8**: p. 986.
33. Rajpal, A., et al., *A general method for greatly improving the affinity of antibodies by using combinatorial libraries.* Proc Natl Acad Sci U S A, 2005. **102**(24): p. 8466-71.
34. Edwards, B.M. and M. He, *Evolution of antibodies in vitro by ribosome display.* Methods Mol Biol, 2012. **907**: p. 281-92.
35. He, M. and M.J. Taussig, *Antibody-ribosome-mRNA (ARM) complexes as efficient selection particles for in vitro display and evolution of antibody combining sites.* Nucleic Acids Res, 1997. **25**(24): p. 5132-4.
36. Newton, M.S., et al., *In Vitro Selection of Peptides and Proteins-Advantages of mRNA Display.* ACS Synth Biol, 2020. **9**(2): p. 181-190.
37. Groves, M.A. and A.A. Nickson, *Affinity maturation of phage display antibody populations using ribosome display.* Methods Mol Biol, 2012. **805**: p. 163-90.
38. Khoshnejad, M., et al., *Molecular engineering of antibodies for site-specific covalent conjugation using CRISPR/Cas9.* Sci Rep, 2018. **8**(1): p. 1760.
39. van der Schoot, J.M.S., et al., *Functional diversification of hybridoma-produced antibodies by CRISPR/HDR genomic engineering.* Sci Adv, 2019. **5**(8): p. eaaw1822.
40. Parola, C., et al., *Antibody discovery and engineering by enhanced CRISPR-Cas9 integration of variable gene cassette libraries in mammalian cells.* MAbs, 2019. **11**(8): p. 1367-1380.
41. Devilder, M.-C., et al., *Ex vivo evolution of human antibodies by CRISPR-X: from a naive B cell repertoire to affinity matured antibodies.* BMC Biotechnology, 2019. **19**(1).
42. Wang, Q., et al., *Application of the CRISPR/Cas9 Gene Editing Method for Modulating Antibody Fucosylation in CHO Cells.* Methods Mol Biol, 2018. **1850**: p. 237-257.
43. Yang, S., et al., *An Antibody-CRISPR/Cas Conjugate Platform for Target-Specific Delivery and Gene Editing in Cancer.* Adv Sci (Weinh), 2024. **11**(21): p. e2308763.
44. Jones, P.T., et al., *Replacing the complementarity-determining regions in a human antibody with those from a mouse.* Nature, 1986. **321**(6069): p. 522-525.
45. Casan, J.M.L., et al., *Anti-CD20 monoclonal antibodies: reviewing a revolution.* Hum Vaccin Immunother, 2018. **14**(12): p. 2820-2841.
46. Slamon, D.J., et al., *Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.* N Engl J Med, 2001. **344**(11): p. 783-92.
47. Lu, R.-M., et al., *Development of therapeutic antibodies for the treatment of diseases.* Journal of Biomedical Science, 2020. **27**(1).
48. Getts, D.R., et al., *Have we overestimated the benefit of human(ized) antibodies?* MAbs, 2010. **2**(6): p. 682-94.
49. Hoogenboom, H.R., *Selecting and screening recombinant antibody libraries.* Nat Biotechnol, 2005. **23**(9): p. 1105-16.
50. McCafferty, J., et al., *Phage antibodies: filamentous phage displaying antibody variable domains.* Nature, 1990. **348**(6301): p. 552-4.
51. Koh, J.H., et al., *Pregnancy and patients with preexisting lupus nephritis: 15 years of experience at a single center in Korea.* Lupus, 2015. **24**(7): p. 764-72.
52. Bates, A. and C.A. Power, *David vs. Goliath: The Structure, Function, and Clinical Prospects of Antibody Fragments.* Antibodies (Basel), 2019. **8**(2).
53. Khilji, S.K., et al., *Smaller size packs a stronger punch - Recent advances in small antibody fragments targeting tumour-associated carbohydrate antigens.* Theranostics, 2023. **13**(9): p. 3041-3063.

54. Saeed, A.F., et al., *Antibody Engineering for Pursuing a Healthier Future.* Front Microbiol, 2017. **8**: p. 495.
55. Kang, J., T. Sun, and Y. Zhang, *Immunotherapeutic progress and application of bispecific antibody in cancer.* Front Immunol, 2022. **13**: p. 1020003.
56. Yu, J., W. Wang, and H. Huang, *Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin's lymphoma: a systemic review and meta-analysis.* Hematology, 2019. **24**(1): p. 199-207.
57. Palecki, J., et al., *T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer.* Cancer Biol Ther, 2024. **25**(1): p. 2356820.
58. Chen, S., et al., *Bispecific antibodies in cancer immunotherapy.* Hum Vaccin Immunother, 2016. **12**(10): p. 2491-2500.
59. Ma, J., et al., *Bispecific Antibodies: From Research to Clinical Application.* Front Immunol, 2021. **12**: p. 626616.
60. Riccardi, F., et al., *A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy.* Frontiers in Pharmacology, 2023. **14**.
61. Fu, Z., et al., *Antibody drug conjugate: the "biological missile" for targeted cancer therapy.* Signal Transduct Target Ther, 2022. **7**(1): p. 93.
62. Sasso, J.M., et al., *The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress.* Bioconjugate Chemistry, 2023. **34**(11): p. 1951-2000.
63. Krop, I. and E.P. Winer, *Trastuzumab Emtansine: A Novel Antibody–Drug Conjugate for HER2-Positive Breast Cancer.* Clinical Cancer Research, 2014. **20**(1): p. 15-20.
64. Tilly, H., et al., *Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.* New England Journal of Medicine, 2022. **386**(4): p. 351-363.
65. Wirt, T., et al., *An Fc Double-Engineered CD20 Antibody with Enhanced Ability to Trigger Complement-Dependent Cytotoxicity and Antibody-Dependent Cell-Mediated Cytotoxicity.* Transfus Med Hemother, 2017. **44**(5): p. 292-300.
66. Li, W., et al., *Crystallizable Fragment Glycoengineering for Therapeutic Antibodies Development.* Front Immunol, 2017. **8**: p. 1554.
67. Hamers-Casterman, C., et al., *Naturally occurring antibodies devoid of light chains.* Nature, 1993. **363**(6428): p. 446-448.
68. Muyldermans, S., *Nanobodies: natural single-domain antibodies.* Annual review of biochemistry, 2013. **82**(1): p. 775-797.
69. Duggan, S., *Caplacizumab: first global approval.* Drugs, 2018. **78**(15): p. 1639-1642.
70. Wang, J., et al., *PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective.* J Hematol Oncol, 2017. **10**(1): p. 34.
71. Wu, K., et al., *The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis.* Exp Hematol Oncol, 2019. **8**: p. 26.
72. He, R., et al., *PD-1 and CTLA-4 inhibitors in combination vs. alone for the treatment of advanced melanoma: A systematic review and meta-analysis.* Medicine (Baltimore), 2022. **101**(41): p. e30561.
73. Silva, L.C., L.C. Ortigosa, and G. Benard, *Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls.* Immunotherapy, 2010. **2**(6): p. 817-33.
74. Monaco, C., et al., *Anti-TNF therapy: past, present and future.* International immunology, 2015. **27**(1): p. 55-62.
75. Gerriets, V., A. Goyal, and K. Khaddour, *Tumor necrosis factor inhibitors.* 2018.
76. Lopetuso, L.R., et al., *Focus on Anti-Tumour Necrosis Factor (TNF)-α-Related Autoimmune Diseases.* International Journal of Molecular Sciences, 2023. **24**(9): p. 8187.
77. Mulangu, S., et al., *A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics.* New England Journal of Medicine, 2019. **381**(24): p. 2293-2303.
78. Misasi, J., et al., *Structural and molecular basis for Ebola virus neutralization by protective human antibodies.* Science, 2016. **351**(6279): p. 1343-1346.
79. Güttler, T., et al., *Neutralization of SARS-CoV-2 by highly potent, hyperthermostable,*

and mutation-tolerant nanobodies. Embo j, 2021. **40**(19): p. e107985.
80. Mahboob, A., et al., *Immunotherapy for Parkinson's Disease and Alzheimer's Disease: A Promising Disease-Modifying Therapy.* Cells, 2024. **13**(18).
81. Alfaidi, M., R.A. Barker, and W.-L. Kuan, *An update on immune-based alpha-synuclein trials in Parkinson's disease.* Journal of neurology, 2025. **272**(1): p. 21.
82. Ghasempour, G., et al., *Efficacy and Safety of Alirocumab and Evolocumab as Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors in Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis.* Curr Med Chem, 2024. **31**(2): p. 223-241.
83. Nelson, D., W. Neill, and I.R. Poxton, *A comparison of immunoblotting, flow cytometry and ELISA to monitor the binding of anti-lipopolysaccharide monoclonal antibodies.* J Immunol Methods, 1990. **133**(2): p. 227-33.
84. Bruce, V.J. and B.R. McNaughton, *Evaluation of Nanobody Conjugates and Protein Fusions as Bioanalytical Reagents.* Anal Chem, 2017. **89**(7): p. 3819-3823.
85. Cedeño-Arias, M., et al., *Validation of a flow cytometry based binding assay for evaluation of monoclonal antibody recognizing EGF receptor.* Sci Pharm, 2011. **79**(3): p. 569-81.
86. Porsch-Özcürümez, M., et al., *Comparison of Enzyme-Linked Immunosorbent Assay, Western Blotting, Microagglutination, Indirect Immunofluorescence Assay, and Flow Cytometry for Serological Diagnosis of Tularemia.* Clinical and Vaccine Immunology, 2004. **11**(6): p. 1008-1015.
87. Police Patil, A.V., et al., *Recent Advances in Electrochemical Immunosensors with Nanomaterial Assistance for Signal Amplification.* Biosensors, 2023. **13**(1): p. 125.
88. Wang, X., et al., *Applications of electrochemical biosensors based on functional antibody-modified screen-printed electrodes: a review.* Analytical Methods, 2022. **14**(1): p. 7-16.
89. Reaño, R.L. and E.C. Escobar, *A review of antibody, aptamer, and nanomaterials synergistic systems for an amplified electrochemical signal.* Frontiers in Bioengineering and Biotechnology, 2024. **12**.
90. Rani, A.Q., et al., *Recent progress in homogeneous immunosensors based on fluorescence or bioluminescence using antibody engineering.* Analyst, 2023. **148**(7): p. 1422-1429.
91. Wei, W., et al., *ImmunoPET: Concept, Design, and Applications.* Chemical Reviews, 2020. **120**(8): p. 3787-3851.
92. Knowles, S.M. and A.M. Wu, *Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology.* J Clin Oncol, 2012. **30**(31): p. 3884-92.
93. He, K., S. Zeng, and L. Qian, *Recent progress in the molecular imaging of therapeutic monoclonal antibodies.* J Pharm Anal, 2020. **10**(5): p. 397-413.
94. Hiraoka, M., *[Companion diagnostics with FISH assay (HER2, ALK)].* Rinsho Byori, 2014. **62**(4): p. 390-8.
95. Wang, Z., et al., *Companion diagnostics and predictive biomarkers for PD-1/PD-L1 immune checkpoint inhibitors therapy in malignant melanoma.* Front Immunol, 2024. **15**: p. 1454720.
96. Almagro, J.C., et al., *Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy.* Frontiers in Immunology, 2018. **8**.
97. Harding, F.A., et al., *The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions.* MAbs, 2010. **2**(3): p. 256-65.
98. Mellstedt, H., *Clinical considerations for biosimilar antibodies.* EJC Suppl, 2013. **11**(3): p. 1-11.
99. van Meer, P.J., et al., *Immunogenicity of mAbs in non-human primates during nonclinical safety assessment.* MAbs, 2013. **5**(5): p. 810-6.
100. Kelley, B., *Industrialization of mAb production technology: the bioprocessing industry at a crossroads.* MAbs, 2009. **1**(5): p. 443-52.
101. Ranbhor, R., *Advancing Monoclonal Antibody Manufacturing: Process Optimization, Cost Reduction Strategies, and Emerging Technologies.* Biologics: Targets and Therapy, 2025. **Volume 19**: p. 177-187.
102. Rabia, L.A., et al., *Understanding and overcoming trade-offs between antibody affinity, specificity, stability and solubility.* Biochem Eng J, 2018. **137**: p. 365-374.

103. Lobo, E.D., R.J. Hansen, and J.P. Balthasar, *Antibody Pharmacokinetics and Pharmacodynamics.* Journal of Pharmaceutical Sciences, 2004. **93**(11): p. 2645-2668.
104. Roopenian, D.C. and S. Akilesh, *FcRn: the neonatal Fc receptor comes of age.* Nature Reviews Immunology, 2007. **7**(9): p. 715-725.
105. Zheng, J., et al., *The Application of Machine Learning on Antibody Discovery and Optimization.* Molecules, 2024. **29**(24): p. 5923.
106. Irvine, E.B. and S.T. Reddy, *Advancing Antibody Engineering through Synthetic Evolution and Machine Learning.* J Immunol, 2024. **212**(2): p. 235-243.
107. Xie, N., et al., *Neoantigens: promising targets for cancer therapy.* Signal Transduct Target Ther, 2023. **8**(1): p. 9.
108. Zhao, Y., et al., *Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy.* J Transl Med, 2023. **21**(1): p. 693.
109. Chung, C., et al., *Expanding the Reach of Monoclonal Antibodies: A Review of Synthetic Nucleic Acid Delivery in Immunotherapy.* Antibodies, 2023. **12**(3): p. 46.
110. Gallo, E., *Revolutionizing Synthetic Antibody Design: Harnessing Artificial Intelligence and Deep Sequencing Big Data for Unprecedented Advances.* Mol Biotechnol, 2025. **67**(2): p. 410-424.
111. Chuang, S.T., et al., *Nanotechnology-enabled immunoengineering approaches to advance therapeutic applications.* Nano Converg, 2022. **9**(1): p. 19.
112. Yu, D., *Translational research: current status, challenges and future strategies.* Am J Transl Res, 2011. **3**(5): p. 422-33.